Studies related to Cognition and Cannabis

Psychopathological And Cognitive Effects Of Therapeutic Cannabinoids In Multiple Sclerosis: A Double-blind, Placebo Controlled, Crossover Study

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 17
Sex Both Genders
Age Range 45-64, 65+
Body Types Average
Notes for this study:
In a double-blind crossover study (one group participating as their own controls) where persons with multiple sclerosis used cannabis or placebo (sublingual application of both to a point where perceived muscular spasticity was reduced) noted that there were no differences between groups on cognitive tests or psychopathological scores.

Given tests were the PASAT (Paced Auditory Serial Additional Test) and MSFC (Multiple Sclerosis Functional Composite) with the former testing auditory information processing speed and calculation ability.

General symptoms of MS (fatigue, leg and arm function, quality of life, physical impairment) did not differ between study periods.

Full details on all 6 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.